Cryptococcal Meningitis

Etiology

Cryptococcal meningitis is caused by central nervous system infection with encapsulated yeasts of the genus Cryptococcus, predominantly Cryptococcus neoformans and Cryptococcus gattii.[1][3] Among more than 50 described Cryptococcus species, these 2 account for the vast majority of human disease.[1][4]

Human infection is typically acquired through inhalation of aerosolized desiccated yeast cells or basidiospores from environmental reservoirs, leading to an initial pulmonary infection that may be asymptomatic, remain latent for years, or manifest as mild respiratory illness.[4][5] Environmental niches include soil contaminated by bird droppings (classically associated with C neoformans) and decaying wood and soil in endemic ecological regions (more commonly implicated in C gattii outbreaks).[4][5] Following primary pulmonary acquisition, cryptococcal meningitis develops through hematogenous dissemination and neuroinvasion in the setting of impaired host defenses, particularly defects in T cell–mediated immunity.[3][6][7]

The most important predisposing condition worldwide is advanced HIV infection, with the highest risk occurring at CD4 counts less than 100 cells/mm³.[3][6] However, cryptococcal meningitis also occurs in individuals without HIV, especially those receiving immunosuppressive therapies (eg, systemic glucocorticoids; biologic agents including antitumor necrosis factor therapies), solid organ transplant recipients, and patients with immune-dysregulating conditions such as sarcoidosis or idiopathic CD4 lymphopenia.[3][4][6] A spectrum of primary and acquired immunodeficiencies has also been associated with cryptococcosis, including monogenic disorders (eg, GATA2 deficiency, chronic granulomatous disease, hyper-IgE syndromes, and CD40L deficiency) and immune phenotypes linked to specific autoantibodies (eg, anti–interferon-gamma).[6]

Disease development involves progression from newly acquired pulmonary infection to dissemination and central nervous system invasion, as well as reactivation of latent infection acquired earlier in life. Advanced immunosuppression, including AIDS, strongly increases the risk of latent infection reactivation.[3][4] C gattii deserves special consideration because this pathogen is more frequently reported in apparently immunocompetent hosts and has been associated with specific geographic regions (including the Pacific Northwest of North America) and with pulmonary cryptococcomas and CNS disease.[4][8]

Epidemiology

Cryptococcal meningitis remains a major global cause of adult meningitis and infectious mortality, particularly in regions with a high prevalence of advanced HIV disease. Globally, cryptococcal disease is responsible for a substantial proportion of AIDS-related deaths each year, with estimates of up to approximately 180,000 deaths annually and roughly one-fifth of all AIDS-related mortality despite expanded access to antiretroviral therapy.[3][9]

The global burden is unevenly distributed. The highest incidence occurs in sub-Saharan Africa and other low- and middle-income regions, where advanced HIV infection, especially with CD4 counts less than 100 cells/mm³, as defined in prior sections, is the dominant epidemiologic driver of cryptococcal meningitis.[3][9] In these settings, delayed diagnosis, limited access to cryptococcal antigen screening, antifungal therapy, and ICP monitoring contribute to high early mortality. 10-week mortality commonly ranges from approximately 24% to 50% in low-resource environments.[3][10]

In higher-income regions, the epidemiology has shifted over time. Although HIV-associated disease remains important, an increasing proportion of cases now occur in non-HIV immunocompromised populations, including solid organ transplant recipients, patients receiving prolonged glucocorticoid therapy, individuals with malignancy, advanced liver disease, and those with immune-mediated disorders such as sarcoidosis.[2][10] In these settings, cryptococcal meningitis is also increasingly recognized in patients receiving other immunosuppressive or biologic therapies. A smaller but clinically significant fraction of cases occurs in apparently immunocompetent hosts.[10]

From a species-distribution perspective, Cryptococcus neoformans is responsible for the majority of cases worldwide and has a broad global distribution. Cryptococcus gattii accounts for a smaller proportion of cases but has distinct geographic clustering and is more frequently associated with disease in immunocompetent hosts and with focal pulmonary or CNS mass lesions. Geographic variation in species complexes and genotype distribution is well documented and contributes to regional epidemiologic differences.[11] Person-to-person spread has not been documented except in the setting of infected transplanted tissue.[11]

Despite advances in diagnostics and antifungal therapy, mortality remains substantial even in resource-rich countries, where reported 10-week mortality typically ranges from about 10% to 25%, consistent with outcome ranges reported elsewhere in this manuscript. Survivors frequently experience long-term neurologic and functional impairment, underscoring the persistent epidemiologic and public health impact of the disease.[3][10]

Pathophysiology

Cryptococcal meningoencephalitis is the end result of pulmonary acquisition with subsequent survival in the host, hematogenous dissemination, and neuroinvasion with persistence within the CNS, particularly when T cell–mediated immunity is impaired. Neurotropism reflects both fungal virulence traits and host immune dysfunction rather than direct tissue cytotoxicity early in infection.[6][12] After inhalation and pulmonary establishment, organisms can survive within macrophages and disseminate during periods of impaired cellular immunity. The polysaccharide capsule and melanin are major virulence factors that promote immune evasion, resistance to oxidative stress, and persistence in hostile host environments, including within phagocytes.[12][13][14]

CNS entry is facilitated through multiple, nonmutually exclusive pathways across the blood-brain barrier, including transcytosis, paracellular traversal, and “Trojan horse” transport within phagocytes. Microanatomic patterns of CNS involvement (diffuse meningoencephalitis versus focal lesions, eg, cryptococcomas) reflect the interaction among inoculum, organismal factors, and host immune response.[15][16][17]

Once in the CNS, cryptococcus proliferates predominantly in the subarachnoid space and perivascular regions. In advanced HIV and other profoundly immunosuppressed states, high fungal burdens may be accompanied by minimal CSF inflammation. Conversely, in patients with more intact immunity, or following immune restoration, exuberant inflammatory responses can drive tissue injury and clinical worsening, including IRIS and postinfectious inflammatory response syndromes described in non-HIV hosts.[18][19][20]

Several organism-specific metabolic and enzymatic pathways facilitate survival and persistence in the CNS microenvironment. Prior mechanisms, including cryptococcal factors that facilitate blood-brain barrier permeability (eg, urease and metalloproteinases) and adaptations to nutrient limitation (eg, autophagy-related mechanisms and high-affinity transport systems), remain aligned with contemporary models in which neuroinvasion and persistence are multifactorial processes.[15][16]

Emerging work also highlights immunometabolic interactions that may modulate neuroinflammation and barrier integrity, including host metabolic states (eg, iron-related effects and inositol-linked pathways) and gut microbiota–derived metabolites that influence blood-brain barrier function and CNS inflammatory tone. These concepts are best interpreted as mechanistic adjuncts rather than primary explanatory drivers in routine bedside decision-making.[21]

Raised ICP is a frequent and clinically decisive complication and is thought to result primarily from impaired CSF resorption due to high organism burden and accumulation of capsular polysaccharide, rather than frank cerebral edema alone. This mechanistic framework supports the clinical emphasis on early recognition and active management of CSF pressure during therapy.[12][17][22] Histopathologically and clinically, little necrosis or overt organ damage may occur until later in the disease; dysfunction can be driven by mass effect and tissue distortion from the fungal burden and host inflammatory sequelae.[23]

Histopathology

Histopathologic examination classically demonstrates round-to-oval, narrow-based budding yeasts within the leptomeninges, subarachnoid space, and perivascular (Virchow–Robin) spaces; organisms may also be seen in the brain parenchyma, particularly in focal lesions (cryptococcomas). In tissue and culture, each yeast cell is surrounded by a prominent polysaccharide capsule that contributes to immune evasion and may vary in conspicuousness depending on host immune status and organism burden.[7][8][13]

Special stains facilitate identification and distinction from other fungi. Gomori methenamine silver and periodic acid–Schiff stains highlight fungal cell walls and aid detection in paucicellular specimens, while the capsule can provide a characteristic “halo” appearance on routine histology and can be emphasized with capsule-directed stains in many laboratories.[24] A diagnostically helpful morphologic clue in cryptococcal infection is a “dented-appearing” yeast contour, a feature commonly reported in cryptococcosis and rarely in other fungal infections, which supports distinction from small intracellular yeasts, eg, Histoplasma capsulatum, when morphology overlaps.[25]

The inflammatory pattern is strongly host dependent. In advanced HIV and other profoundly immunosuppressed states, tissue sections often show a high fungal burden with minimal inflammatory response (“paucicellular” or gelatinous-appearing lesions). In contrast, in immunocompetent or partially immune hosts, granulomatous inflammation with multinucleated giant cells and more localized mass lesions (cryptococcomas) may be present; cryptococcomas are reported more frequently with Cryptococcus gattii.[7][8] Histopathologic evidence of tissue invasion is sufficient for diagnosis even when cultures are negative; however, atypical or overlapping morphologies can produce diagnostic error. In challenging cases, integrated approaches that combine histopathology with antigen testing and molecular methods (eg, PCR/sequencing) improve diagnostic accuracy and may assist with species-level confirmation.[10][25]

History and Physical

Cryptococcal meningitis most often presents as a subacute meningoencephalitis, with symptom tempo and exam findings influenced by the host immune state and fungal burden. In patients with advanced HIV, symptoms often evolve over approximately 2 weeks and may be subtle initially; in patients without HIV, presentations are frequently subacute over 2 to 4 weeks, though some patients have more indolent courses and delayed recognition.[26][27]

Clinical History

Risk assessment should be integrated into the initial history and should specifically query for conditions associated with impaired cell-mediated immunity, as described previously. In patients without an established risk factor, clinicians should consider occult immunodeficiency alongside the diagnostic evaluation.[10]

Core neurologic symptoms typically include:

• Headache (often persistent and progressive) and fever are frequently accompanied by malaise and constitutional symptoms.[27][28]

• Symptoms of ICP, eg, nausea/vomiting, lethargy, and altered mentation; patients may describe cognitive slowing, personality changes, or memory impairment, particularly in advanced HIV, where meningeal irritation can be minimal.[29][30]

• Meningeal symptoms (eg, neck stiffness, photophobia) may occur but are not universal and can be absent even in microbiologically confirmed disease, especially in advanced HIV.[29][30]

Focal neurologic symptoms may reflect parenchymal involvement, hydrocephalus, or focal lesions (eg, cryptococcoma). Symptoms can include seizures, focal weakness, ataxia, aphasia, or other focal deficits, and should be explicitly screened for because they influence urgency and downstream evaluation pathways.[26][27] Visual and auditory symptoms are clinically important because they may signal elevated ICP or cranial neuropathies. Patients may report diplopia, blurred vision, photophobia, or reduced visual acuity; less commonly, they report hearing changes or vestibular symptoms.[26][27]

Disseminated disease review of systems should assess extra-CNS involvement to identify diagnostic clues, including pulmonary symptoms (eg, cough, dyspnea, or chest discomfort) that may accompany or precede central nervous system disease, and cutaneous findings (eg, papules or nodular lesions, sometimes umbilicated), suggestive of disseminated cryptococcosis.[6][10][30] IRIS-related presentations (HIV) should be considered when symptoms occur after starting or restarting antiretroviral therapy. New or worsening headache, fever, or neurologic deficits in the setting of recent immune recovery may represent unmasking or paradoxical cryptococcal IRIS rather than antifungal failure, and should be explicitly asked about in the timeline history.[31][32][33]

Physical Examination

The physical examination should prioritize neurologic severity assessment and signs of elevated ICP, including:

• Vital signs and general appearance: Fever may be present, but the absence of fever does not exclude cryptococcal meningitis, particularly in profoundly immunosuppressed hosts.[27][28]

• Mental status: Clinicians should carefully document orientation, attention, short-term memory, and level of consciousness; altered mentation is common and may be the dominant presenting abnormality in advanced HIV.[28][30]

• Meningeal signs: assess for nuchal rigidity and photophobia, recognizing that these signs may be absent even in established disease, particularly with a high fungal burden and a limited inflammatory response.[29][30]

• Cranial nerve examination: Cranial neuropathies (eg, diplopia consistent with sixth nerve palsy) should be noted, which can reflect elevated ICP or basilar meningeal involvement.[26][30]

• Funduscopic examination: Clinicians should evaluate for papilledema when feasible; its presence supports raised ICP and informs urgency and diagnostic sequencing.[10][30]

• Focal neurologic deficits: Motor, sensory, coordination, gait, and language examination should be performed to identify focal signs suggesting parenchymal disease, hydrocephalus, or mass lesions.[26][27]

Targeted examination for dissemination should include skin assessment for lesions suggestive of disseminated infection and pulmonary evaluation to identify findings consistent with concomitant pulmonary cryptococcosis, recognizing that pulmonary involvement may remain clinically silent.[6][10][30]

Evaluation

Evaluation of suspected cryptococcal meningitis requires a structured, stepwise approach that integrates clinical assessment, CSF analysis, cryptococcal antigen (CrAg) testing, fungal culture, and neuroimaging when indicated. Because disease presentation and inflammatory response vary substantially according to immune status, diagnostic interpretation must be contextualized accordingly.[6][34][27] All patients with suspected or confirmed cryptococcosis should be evaluated for CNS involvement, even when neurologic symptoms are subtle or absent, particularly in individuals with advanced HIV infection or other forms of impaired cell-mediated immunity.[27][34]

Lumbar Puncture and Cerebrospinal Fluid Analysis

Lumbar puncture is essential in all patients with suspected cryptococcal meningitis unless contraindicated. Measurement of opening pressure at the initial procedure is mandatory, as elevated ICP is common and carries important prognostic and therapeutic implications.[6][10] An opening pressure greater than 25 cm H₂O is consistently associated with increased mortality and should prompt immediate management.[6][10]

Routine CSF studies should include cell count with differential, glucose, protein, fungal culture, and CrAg testing. Typical CSF findings include mildly elevated protein, low to normal glucose, and a lymphocytic pleocytosis; however, these features may be absent in patients with advanced HIV, in whom CSF may appear minimally inflammatory despite high fungal burden.[27][34] A normal CSF profile does not exclude cryptococcal meningitis, particularly in severely immunosuppressed hosts (see Table. Cerebrospinal Fluid Analysis of Central Nervous System Conditions).[34] 

Table. Cerebrospinal Fluid Analysis of Central Nervous System Conditions

Cryptococcal Antigen Testing

Detection of CrAg in CSF or serum is the cornerstone of diagnosis. The lateral flow assay (LFA) is the preferred diagnostic modality due to its rapid turnaround, ease of use, and excellent diagnostic performance. In CSF, CrAg LFA sensitivity and specificity exceed 99%.[3][10] Serum CrAg testing is also highly sensitive and may become positive weeks before the onset of neurologic symptoms, making it useful for screening and for initial evaluation when lumbar puncture must be delayed.[10][3]

High serum CrAg titers, particularly 1:640 or more by LFA, are strongly associated with disseminated infection and CNS involvement in patients with HIV and should prompt urgent lumbar puncture and evaluation for meningitis, even in the absence of overt neurologic symptoms.[30][34] Latex agglutination and enzyme immunoassay methods are acceptable alternatives but are less commonly used due to lower practicality and longer processing times.[30]

Notably, individuals with a high cryptococcal CSF burden may exhibit a "false negative" result, especially for those with advanced HIV. Persons with symptomatic meningitis, or even silent meningitis but at risk for severe disease, with a positive serum CrAg, should have dilutions performed of the CSF to rule out the prozone phenomenon.[35]

Microscopy and Fungal Culture

India ink microscopy of CSF can provide a rapid presumptive diagnosis by demonstrating encapsulated yeasts, but its sensitivity is limited (approximately 60%–86%) and is highly dependent on fungal burden. Its diagnostic yield is lowest in early disease and in non-HIV populations, and many centers now rely primarily on antigen testing.[30][34]

CSF fungal culture remains the gold standard for confirming the presence of viable organisms and is essential for documenting microbiologic clearance and for evaluating suspected treatment failure or relapse. CSF cultures are positive in approximately 90% to 94% of HIV-associated cases, while blood cultures are positive in 47% to 70% of disseminated disease.[3][30][34] Culture also permits species identification and antifungal susceptibility testing when clinically indicated.

Neuroimaging

Brain imaging with MRI (preferred) or CT should be performed before lumbar puncture in patients with focal neurologic deficits, papilledema, new seizures, altered consciousness, or other features suggesting mass effect or obstructive hydrocephalus.[6][27][34]Neuroimaging may demonstrate cryptococcomas, hydrocephalus, dilated perivascular spaces, or nonspecific meningeal enhancement, but normal imaging does not exclude cryptococcal meningitis.[34] Neuroimaging also plays an important role in evaluating clinical deterioration during therapy, particularly when IRIS or a postinfectious inflammatory response is suspected.[18]

Adjunctive Laboratory Evaluation

All patients should undergo HIV testing if their status is unknown. In HIV-positive individuals, CD4 cell count and HIV viral load are essential, as cryptococcal meningitis is an AIDS-defining illness, and immune status directly influences prognosis and timing of antiretroviral therapy initiation.[6][34] Additional evaluation may include blood cultures, chest imaging to assess for pulmonary or disseminated disease, and targeted testing for alternative causes of chronic meningitis (eg, tuberculosis, syphilis, histoplasmosis) based on epidemiologic and clinical context.[6][10][27]

Treatment / Management

Treatment of cryptococcal meningoencephalitis is based on rapid fungal clearance from CSF and aggressive management of ICP, followed by prolonged azole therapy to prevent relapse. Modern management is best conceptualized as 3 antifungal phases (induction → consolidation → maintenance), with regimen selection and duration guided primarily by host category, resource setting, and presence of cryptococcoma/Cryptococcus gattii disease.[3][10][36][37](A1)

Antifungal Therapy: General Principles

The primary antifungal agents used for cryptococcal meningitis include amphotericin B (AmB) (preferably lipid formulations), flucytosine (5-FC), and fluconazole.[10][37] Amphotericin B plus flucytosine remains the most rapidly fungicidal combination and is associated with improved survival compared with amphotericin monotherapy.[38][39][40](A1)

Fluconazole is fungistatic and should not be used as the sole therapy for induction unless no other options exist.[36][41] Intrathecal or intraventricular amphotericin B is not recommended except in extreme circumstances, due to toxicity (eg, arachnoiditis) and the effectiveness of systemic therapy.[42](A1)

Induction Therapy in HIV-Associated Cryptococcal Meningoencephalitis

Induction therapy during the first 2 weeks of most HIV-associated cryptococcal meningoencephalitis in resource-rich settings relies on combination antifungal treatment. Preferred induction therapy includes liposomal amphotericin B at 3 to 4 mg/kg intravenously (IV) daily combined with flucytosine at 100 mg/kg/day orally 4 times daily for 2 weeks.[3][10][36] (A1)

An alternative lipid formulation option includes amphotericin B lipid complex at 5 mg/kg IV daily, combined with flucytosine at 100 mg/kg/day orally 4 times daily) for 2 weeks.[10][43] Lipid amphotericin formulations are preferred over amphotericin B deoxycholate due to reduced nephrotoxicity and improved ability to complete uninterrupted induction therapy.[43][44]

HIV-Associated Disease (Resource-Limited Settings)

HIV-associated cryptococcal disease management in low- and middle-income settings follows a WHO-endorsed strategy supported by the AMBITION-cm trial. Recommended therapy includes a single high-dose liposomal amphotericin B dose of 10 mg/kg IV once, combined with flucytosine 100 mg/kg/day orally 4 times daily and fluconazole 1200 mg/day by mouth for 14 days.[3][10][41]

When flucytosine is unavailable, amphotericin B deoxycholate at 0.7 to 1 mg/kg/day IV, combined with fluconazole 800 to 1200 mg/day orally for 2 weeks, may be used, with recognition that this regimen is less effective than 5-FC-containing regimens.[3][41] When amphotericin is unavailable, combination therapy with fluconazole 800 to 1200 mg/day plus flucytosine 100 mg/kg/day 4 times daily remains preferred over fluconazole monotherapy.[41] Fluconazole monotherapy at 1200 mg/day represents the least effective induction strategy and should be reserved only for situations where no alternative treatment options exist.[41]

Induction Therapy in Patients Without HIV, Solid Organ Transplant Recipients, and Other Non-HIV Immunocompromised Hosts

In non-HIV patients, fungal clearance is typically slower; induction therapy is therefore longer and is commonly continued for 4 to 6 weeks, or until at least 2 weeks after CSF culture sterilization, with flucytosine generally given for the first 2 weeks.[3][10][20] Preferred induction therapy is liposomal amphotericin B 3 to 5 mg/kg/day IV plus flucytosine 100 mg/kg/day orally 4 times daily for 4 to 6 weeks.[3][10] An alternative regimen is amphotericin B deoxycholate 0.7 to 1 mg/kg/day IV plus flucytosine 100 mg/kg/day orally 4 times daily, which may be used if lipid formulations are unavailable, but the risk of nephrotoxicity is higher.[3][20](A1)

Immunocompetent Hosts

Induction therapy is similar to that of non-HIV immunocompromised hosts, with 4 to 6 weeks commonly required due to slower clearance.[3][10][20](A1)

Cryptococcus gattii Central Nervous System Disease or Cryptococcoma

Induction therapy should be extended (often 4–6 weeks), especially if CSF cultures remain positive at 2 weeks or if cryptococcoma is present.[10]

Consolidation Therapy

After successful induction, consolidation therapy typically consists of fluconazole 400 to 800 mg/day by mouth for at least 8 weeks.[3][10][36] In HIV-associated disease, some regimens include 800 mg/day early (particularly before antiretroviral therapy initiation), followed by step-down, but consolidation should remain a structured phase lasting approximately 8 weeks total.[22](A1)

Maintenance (Suppressive) Therapy

Maintenance therapy is essential to prevent relapse, especially in HIV-associated disease, fluconazole 200 mg/day orally for 12 months or more.[3][10][36] In HIV-infected patients, discontinuation of maintenance therapy may be considered after at least 1 year of therapy, a CD4 count higher than 100 cells/mm³, and sustained HIV viral suppression on antiretroviral therapy (ART).[3][10](A1)

Monitoring During Therapy 

Monitoring during therapy includes reassessment of cerebrospinal fluid status and close surveillance for antifungal toxicities. A repeat lumbar puncture is commonly performed after 2 weeks of induction therapy to confirm sterility of the cerebrospinal fluid culture, particularly in resource-rich settings and before initiation of antiretroviral therapy.[10] In resource-limited settings, routine repeat lumbar puncture to confirm sterilization may not be feasible, making clinical response the primary determinant of ongoing management decisions.[41]

Flucytosine Toxicity Monitoring

Flucytosine toxicity monitoring requires careful attention to renal function, since toxicity risk increases with renal impairment, including amphotericin-associated nephrotoxicity. Recommended monitoring includes complete blood count 2 to 3 times per week as an indirect marker of toxicity when drug levels are unavailable.[45] When serum levels can be measured, target peak concentrations range from 30 to 80 µg/mL, with avoidance of levels exceeding 100 µg/mL; dose reduction is necessary with worsening renal function.[45] Fluconazole is generally well tolerated but can cause hepatotoxicity, particularly at higher doses (>800 mg/day). Liver enzymes should be monitored periodically during prolonged therapy.[45]

Management of Intracranial Pressure

ICP management is one of the most important determinants of outcome in cryptococcal meningoencephalitis and should be treated as a core therapeutic intervention, not an adjunct.[20] The opening pressure must be measured at the time of the initial lumbar puncture.[6][20] An opening pressure of 25 cm H₂O or more with symptoms warrants therapeutic drainage.[6][20](A1)

Recommended management strategies include draining CSF to reduce pressure by 50% if extremely high, or to a target of 20 cm  H₂O or more.[20] Repeat therapeutic lumbar drainage daily for persistent symptomatic pressure elevations 25 cm H₂O or higher until stable for more than 2 days.[20] If repeated lumbar punctures are required, temporary percutaneous lumbar drains or ventriculostomy may be appropriate.[20] If conservative measures fail despite appropriate antifungal therapy, ventriculoperitoneal shunting may be warranted, particularly in obstructive hydrocephalus.[20] Mannitol and acetazolamide should not be used for the management of elevated intracranial pressure because these agents provide no clinical benefit and may worsen electrolyte abnormalities, particularly during amphotericin therapy.[20](A1)

Adjunctive Corticosteroids

Adjunctive corticosteroids should not be used as routine initial therapy for cryptococcal meningitis.[19][20] A randomized trial involving 451 patients with HIV-associated cryptococcal meningitis evaluated adjunctive dexamethasone initiated at 0.3 mg/kg/day and tapered over 6 weeks. Results showed no improvement in mortality or immune reconstitution inflammatory syndrome outcomes at 10 weeks.(A1)

Dexamethasone use also correlated with worse neurologic outcomes, slower cerebrospinal fluid fungal clearance, and increased adverse events, including infections and renal or cardiac complications.[19] Corticosteroids may still have a role in selected inflammatory complications, eg, paradoxical immune reconstitution inflammatory syndrome or severe inflammatory cryptococcoma, but routine use during induction therapy should be avoided.[20][46](A1)

Timing of Antiretroviral Therapy in HIV

Immune recovery with antiretroviral therapy (ART) is essential for long-term control, but premature initiation increases the risk of IRIS. ART should generally be started between 2 and 10 weeks after antifungal therapy begins, with many resource-limited protocols initiating at 4 to 6 weeks.[10][19](B2)

Persistent Infection, Relapse, and Drug Resistance Considerations

Clinical deterioration or persistent symptoms following initial improvement warrant reassessment with a repeat lumbar puncture to evaluate for elevated intracranial pressure and persistent or relapsed fungal infection.[46] Among patients receiving ART, increased intracranial pressure and cerebrospinal fluid pleocytosis in the setting of sterile cultures suggest paradoxical immune reconstitution inflammatory syndrome.[46]

Evaluation for suspected antifungal resistance should include collection of an on-treatment isolate with comparison of minimum inhibitory concentration values to baseline measurements. A 3-fold increase in minimum inhibitory concentration suggests emerging resistance. Absolute minimum inhibitory concentration thresholds, including values 16 µg/mL or more for fluconazole or 32 µg/mL or greater for flucytosine, may also raise concern despite the absence of definitive clinical breakpoints.[46] Alternative azole agents used in refractory or resistant disease, although supported by limited evidence, include voriconazole, posaconazole, and isavuconazole.[46]

Differential Diagnosis

The differential diagnosis of cryptococcal meningoencephalitis is broad because its clinical syndrome overlaps substantially with other causes of subacute and chronic meningitis and with intracranial mass lesions. Misdiagnosis is common in advanced HIV infection, where multiple opportunistic infections and malignancies can coexist, and in non-HIV immunocompromised hosts, where meningeal signs may be absent, and the onset is often indolent.[47]

A practical diagnostic framework groups competing conditions into 2 major categories: subacute or chronic meningitis syndromes and intracranial mass lesions, particularly when neuroimaging demonstrates focal lesions or cerebral edema.[47]

Key Infectious Mimickers

Tuberculous meningitis

Tuberculous meningitis is among the most important mimickers worldwide and often presents with subacute headache, fever, progressive altered mentation, and cranial neuropathies. Clinical clues include risk of tuberculosis exposure, constitutional symptoms, pulmonary symptoms (eg, cough, hemoptysis), and abnormal chest imaging.[48] Compared with cryptococcal meningoencephalitis, tuberculous meningitis more often features basilar meningeal involvement, hydrocephalus, and stroke-like complications from vasculitis.[48]

Other endemic and opportunistic fungal meningitides

Other fungal infections can present with a similar subacute and chronic meningitis syndrome and overlapping CSF profiles. These diagnoses should be prioritized in patients with compatible geographic exposures or systemic features.[47]

Important fungal mimickers include:

• Histoplasma capsulatum, particularly in disseminated disease with systemic features (eg, pulmonary involvement, cytopenias, hepatosplenomegaly)

• Coccidioides immitis/posadasii, especially in patients with endemic exposure history and chronic course [49]

• Candida species, particularly in neurosurgical patients or those with indwelling CNS devices [24]

• Aspergillus species, typically with focal parenchymal disease or hemorrhagic infarcts in severely immunocompromised hosts [24]

In these entities, cryptococcal antigen testing is negative, and confirmatory testing relies on organism-specific antigen/antibody assays, fungal culture, or tissue diagnosis, depending on the syndrome.[24][49]

Partially treated bacterial meningitis

Partially treated bacterial meningitis can evolve into a subacute presentation when antibiotics are administered before lumbar puncture. This diagnosis is suggested by a more acute onset, a history of recent antibiotic exposure, and a CSF profile that is neutrophil-predominant early or mixed.[50]

Neurosyphilis

Neurosyphilis may present as subacute meningitis, meningovascular disease (stroke-like symptoms), or late neuropsychiatric syndromes. In advanced HIV infection, neurosyphilis remains an important alternative diagnosis and can overlap clinically with cryptococcal disease.[47] Patients with secondary syphilis and aseptic meningitis often have relatively preserved mentation and a disseminated maculopapular rash.

Viral CNS syndromes in advanced immunosuppression

In advanced HIV infection, progressive multifocal leukoencephalopathy (PML) and viral encephalitides can overlap with cryptococcal meningoencephalitis through shared features of altered mentation and neurologic deficits.

Intracranial mass lesions and focal neurologic syndromes

When neuroimaging reveals mass lesions, clinicians should broaden the differential beyond cryptococcal meningitis, particularly in advanced HIV. Key competing diagnoses include:

• Toxoplasma gondii encephalitis (often focal deficits; ring-enhancing lesions) [51]

• Primary CNS lymphoma (focal deficits; tumor-like lesions on imaging)

• Tuberculomas or tuberculous meningitis with focal lesions [48]

In contrast, mass lesions due to Cryptococcus neoformans are uncommon in patients with HIV who are not receiving antiretroviral therapy. However, they may occur in unmasking IRIS and in Cryptococcus gattii infection.

Additional Considerations in High-Risk Hosts

In advanced HIV, the differential diagnosis of fever and headache commonly includes toxoplasmosis, tuberculous meningitis, CNS lymphoma, syphilis, and PML. A helpful bedside clue is that toxoplasmosis more often produces focal deficits (eg, limb weakness), whereas cryptococcal meningoencephalitis more commonly produces cranial neuropathies, particularly sixth nerve palsy, reflecting raised ICP.

Noninfectious Mimickers

Although infections account for the majority of subacute and chronic meningitis in high-risk hosts, noninfectious inflammatory and malignant etiologies remain important mimickers and may coexist with opportunistic infections.[47] Diagnostic evaluation should also consider neoplastic meningitis or leptomeningeal carcinomatosis, which commonly presents with progressive cranial neuropathies and malignant cells in cerebrospinal fluid.[52][47] Inflammatory disorders, eg, neurosarcoidosis, may produce cranial neuropathies, systemic sarcoidosis manifestations, and inflammatory cerebrospinal fluid findings.[53] Primary central nervous system vasculitis and secondary vasculitic syndromes may present with stroke-like episodes and multifocal neurologic deficits, further complicating the differential diagnosis.[47]

Diagnostic Anchors That Narrow the Differential

Because clinical findings are nonspecific, diagnostic anchoring relies on targeted testing already detailed in the Evaluation chapter. Key points that narrow the differential include:

• CSF cryptococcal antigen positivity, which is highly sensitive and specific for cryptococcal CNS infection and rapidly distinguishes cryptococcosis from tuberculosis, other fungi, and noninfectious etiologies.[6]

• Recognition of false-positive cryptococcal antigen tests, which have been reported with certain organisms (eg, Trichosporon) and rare specimen contamination issues, particularly with latex agglutination methods; discordant results warrant repeat testing and clinical correlation.

Prognosis

Prognosis in cryptococcal meningitis is primarily determined by host immune status, baseline neurologic severity, fungal burden, ICP physiology, timeliness of diagnosis, and access to optimal induction therapy plus ICP-directed supportive care. Early deaths cluster in the first 2 weeks, most often linked to uncontrolled elevated ICP and high organism burden.[2][6][54][55][56]

Overall Outcomes and Mortality Patterns

HIV-associated cryptococcal disease in resource-limited settings demonstrates substantial variability in 10-week mortality according to induction regimen. Fluconazole monotherapy produces the poorest outcomes, with 10-week mortality approaching approximately 70% across multiple African settings.[54] Optimized amphotericin-based strategies have improved short-term survival, including short-course amphotericin B deoxycholate combined with flucytosine, followed by fluconazole, in the ACTA trial, and single-dose liposomal amphotericin B at 10 mg/kg combined with 14 days of flucytosine and fluconazole in the AMBITION-cm trial. Both major African trials reported approximately 25% 10-week mortality.[55][57] Despite these advances, early mortality remains high, with 2-week mortality commonly ranging from approximately 17% to 26% even in contemporary amphotericin-based trial settings.[55][56]

Outcomes among non-HIV immunocompromised hosts remain heterogeneous and strongly reflect comorbidity burden and delayed recognition. Solid organ transplant recipients demonstrate variable in-hospital and 90-day mortality across studies, while HIV-seronegative cohorts consistently associate older age and concurrent fungemia or meningitis with increased short-term case fatality.[58][59][60] Delayed diagnosis and impaired immune responses remain major contributors to adverse outcomes in non-HIV populations.[36]

High-income settings benefit from access to liposomal amphotericin B, laboratory monitoring, and aggressive intracranial pressure management, all of which correlate with lower short-term mortality; however, clinically significant mortality persists across cohorts.[8][10][36] Global disparities in outcomes reflect not only differences in antifungal availability but also variation in the ability to measure opening pressure, perform serial therapeutic lumbar punctures, monitor medication toxicities, and deliver comprehensive supportive care.[61][62]

Major Predictors of Poor Prognosis

Prognostic factors can be grouped into the following categories:

• Clinical severity (highest-yield bedside predictors)
  • Altered mental status / impaired consciousness is among the most consistent predictors of early mortality across populations.[56][63][64][65]
  • Advanced age is associated with increased early mortality risk in multiple cohorts.[56][61]
  • Delayed diagnosis (prolonged symptom duration before recognition) is associated with worse neurologic outcomes and higher mortality risk.[66]

• CSF physiology and inflammatory response
  • Opening pressure ≥25 cm H₂O is associated with increased mortality risk and is a key, modifiable determinant of outcome through therapeutic drainage strategies described elsewhere in this manuscript.[6][59]
  • Inadequate ICP control is strongly linked to early deaths in trial settings and remains a major driver of both mortality and long-term disability.[3]
  • Low CSF WBC count (reflecting poor inflammatory response in advanced immunosuppression) is associated with poor outcomes and, in some cohorts, a higher likelihood of culture-positive relapse rather than inflammatory syndromes.[64][67][68]
  • CSF lactate >5 mmol/L has been reported as an independent marker of excess mortality in some settings and may help identify very high-risk patients at presentation.[69]

• Fungal burden and dissemination
  • High baseline CSF fungal burden and slow early clearance predict higher mortality.[56]
  • Cryptococcemia/positive blood cultures (disseminated disease marker) is associated with a higher mortality risk.[59]

• Imaging and neurologic complications
  • Imaging findings indicating hydrocephalus or cryptococcoma (and other structural complications) are associated with worse outcomes and may signal the need for more intensive supportive and procedural management pathways addressed elsewhere in the manuscript.[70]

• Health-system and regimen-related factors
  • Suboptimal induction therapy and delayed initiation of effective antifungal treatment worsen outcomes.[56]
  • Limited access to flucytosine contributes to higher mortality in many settings, consistent with trial and pooled analyses demonstrating improved survival when flucytosine is incorporated into induction regimens.[61][71]

Long-Term Neurologic and Functional Outcomes

Among survivors, persistent neurologic morbidity is common, including cognitive impairment, cranial neuropathies, visual loss, and functional disability. In some cohorts, a majority of survivors demonstrate cognitive or physical impairment at 12 months, with wide variability across settings and host populations.[8][66][72][73] Elevated ICP and delays in diagnosis are associated with a higher risk of long-term neurologic sequelae, reinforcing the prognostic importance of early recognition and aggressive ICP management.[3][66]

Relapse, Persistent Infection, and IRIS-Related Prognostic Implications

Clinical worsening after initial improvement requires careful distinction between microbiologic persistence/relapse and inflammatory syndromes (eg, paradoxical IRIS in HIV or post-infectious inflammatory response in selected non-HIV hosts). Culture-positive relapse is associated with substantial subsequent mortality in reported cohorts, and risk is increased by inadequate induction therapy, premature discontinuation/nonadherence to suppressive therapy, and poor immune reconstitution (eg, very low CD4 counts and low CSF WBC). This manuscript’s management framework (repeat lumbar puncture with opening pressure and culture) remains central to prognostic reassessment in such scenarios.[6][10][67]

Practical Bedside Risk Stratification

Patients are at particularly high risk for early mortality when presenting with combinations of the following:

• Altered mental status / impaired consciousness [56][64][65]

• Opening pressure ≥25 cm H₂O or clinical features of uncontrolled ICP [3][6][59]

• Low CSF WBC count suggesting profoundly impaired inflammatory response [64][67][68]

• High CSF fungal burden or evidence of dissemination (cryptococcemia) [56][59]

• Delayed diagnosis or receipt of suboptimal induction therapy [56][66]

Conversely, earlier diagnosis, access to optimized induction regimens including flucytosine, and consistent ICP-directed supportive care improve short-term survival. However, meaningful long-term neurologic morbidity may persist despite microbiologic control.[8][55][57][71]

Complications

Cryptococcal meningoencephalitis is associated with acute life-threatening complications, infectious failure syndromes, immune-mediated inflammatory complications during immune recovery, treatment-related toxicities, and long-term neurologic sequelae. Early clinical deterioration should prompt a structured reassessment that prioritizes ICP physiology, microbiologic status by CSF culture, and neuroimaging when focal deficits, seizures, or hydrocephalus are suspected.[6]

Acute Severe Complications

Acute, life-threatening complications include:

• Raised ICP: Elevated ICP is the most life-threatening acute complication and a major contributor to early mortality. It occurs frequently in HIV-associated disease and is primarily driven by impaired CSF resorption due to high fungal burden and the obstructive effects of capsular polysaccharide. The clinical manifestations, management strategies, and recommendations for reassessment are detailed elsewhere in this manuscript.[3][10]

• Hydrocephalus: Hydrocephalus may be communicating or obstructive. The host phenotype can influence the mechanism. Communicating hydrocephalus is often related to impaired CSF reabsorption, whereas obstructive hydrocephalus may occur with inflammatory obstruction at CSF outflow pathways. Neuroimaging (MRI preferred when available) helps distinguish patterns and assess for transependymal flow or sulcal effacement. Persistent symptomatic raised ICP despite repeated therapeutic lumbar punctures warrants neurosurgical consultation for temporizing drainage (eg, lumbar drain for communicating hydrocephalus; ventriculostomy for obstructive hydrocephalus) and consideration of definitive shunting after effective antifungal therapy is established.[10][51]

• Seizures and acute neurologic deterioration: Seizures may occur in severe disease and should prompt urgent evaluation for contributing drivers: uncontrolled raised ICP, hydrocephalus, infarction, cryptococcoma/mass effect, electrolyte abnormalities, or concurrent CNS pathology. Management requires stabilization, antiseizure therapy as indicated, and targeted evaluation with repeat lumbar puncture (including opening pressure and CSF culture when feasible) and neuroimaging based on clinical severity and focal findings.[8][74][75]

• Stroke and vasculitis-spectrum ischemia: Ischemic stroke, often lacunar and involving basal ganglia structures, can complicate cryptococcal meningitis and is associated with worse neurologic outcomes. New focal deficits, abrupt decline in consciousness, or acute neurologic changes should trigger prompt neuroimaging and evaluation for contributing factors (including hydrocephalus, inflammatory vasculopathy, and metabolic derangements such as hyponatremia and anemia). Supportive management is individualized and should be integrated with continued antifungal therapy and aggressive ICP control when present.[74][75][76][77]

Infectious Complications 

Infectious complications and failure syndromes include:

• Persistent infection/treatment failure: Clinical nonimprovement with continued culture positivity despite appropriate therapy (including ICP management) should raise concern for persistent infection. CSF culture remains the gold standard for confirming microbiologic persistence. Persistently positive CSF cultures after an extended course of proven effective antifungal therapy are a reasonable operational marker of persistent infection and should prompt a structured reassessment of regimen adequacy, adherence, drug exposures, and host factors. Cryptococcal antigen may remain detectable and should generally not be used alone to define failure or to guide escalation.[6][10]

• Microbiologic relapse: Microbiologic relapse is defined by recurrence of symptoms with recovery of viable organisms from CSF after prior documented sterilization, typically after ≥4 weeks of therapy. The most common drivers are inadequate induction therapy, premature discontinuation or nonadherence to consolidation/maintenance therapy, and inadequate immune recovery. When relapse is suspected, evaluation should include neuroimaging when indicated and a repeat lumbar puncture with opening pressure, microscopy, and culture. Review adherence and drug–drug interactions (notably those that reduce azole exposure) and obtain susceptibility testing on relapse isolates when clinically indicated.[6][10]

• Antifungal resistance (uncommon but important in relapse/failure): Primary resistance is uncommon in many settings, but acquired fluconazole resistance can emerge—particularly when fluconazole is used as monotherapy for induction or when azole exposures are subtherapeutic. Susceptibility testing is not routinely required at baseline but is appropriate in persistent infection or relapse. Salvage approaches should be individualized based on susceptibility results and the patient’s clinical course, without substituting for confirmation of CSF culture sterility after reinduction.[10][78][79]

Immune-Mediated Inflammatory Complications

Immune-mediated inflammatory complications include:

• Cryptococcal immune reconstitution inflammatory syndrome (IRIS or C-IRIS) in HIV: IRIS occurs after ART initiation or reinitiation and may be unmasking (symptoms emerge after ART before antifungal therapy) or paradoxical (clinical worsening after antifungal initiation with microbiologic control). Paradoxical IRIS typically develops weeks to months after ART start and presents with worsening headache, fever, neurologic symptoms, or new radiographic lesions despite sterile CSF cultures. Because no definitive biomarker is known, IRIS is a diagnosis of exclusion; repeat lumbar puncture with opening pressure and CSF culture is central to distinguishing IRIS from culture-positive relapse or persistent infection. Management emphasizes continuation of antifungal therapy and ART, aggressive ICP control when present, symptomatic therapy, and consideration of a short course of corticosteroids for severe inflammatory presentations after relapse has been reasonably excluded.[10]

• Postinfectious inflammatory response syndrome (PIIRS) in non-HIV hosts: Some non-HIV patients (including apparently immunocompetent individuals and those with immune recovery or withdrawal of immunosuppression) can develop a postinfectious inflammatory syndrome characterized by clinical worsening or atypical inflammatory manifestations after microbiologic response. Presentations may include arachnoiditis or other inflammatory neurologic complications. When suspected, evaluation should prioritize exclusion of persistent infection by CSF culture and assessment for structural complications on imaging. Corticosteroids may be considered in carefully selected cases when inflammation is driving morbidity and infection has been controlled.[10][24]

• IRIS-like phenomena in solid organ transplant recipients: In transplant recipients, rapid reduction of immunosuppression can precipitate an IRIS-like inflammatory syndrome that mimics relapse. Management requires balancing immunosuppression adjustments against the risk of rejection while maintaining effective antifungal therapy and using diagnostic reassessment (culture-based) to avoid misclassifying inflammatory worsening as microbiologic failure.[10][24]

Focal Disease Complications

Cryptococcomas (space-occupying lesions) are more common in C gattii infection and in patients with more intact immunity, and they may produce focal deficits, seizures, or raised ICP from mass effect. Radiographic lesions can persist despite microbiologic cure; persistent imaging abnormalities alone should not prompt escalation or prolonged therapy in the absence of clinical deterioration. Worsening neurologic symptoms with mass effect despite microbiologic response may warrant adjunctive corticosteroids, and selected large or strategically located lesions may require neurosurgical evaluation for biopsy or resection to exclude alternative pathology or coinfection and to relieve mass effect.[10][80][81]

Treatment-Related Complications

Treatment-related toxicities that may occur include:

• Amphotericin B–associated toxicities: Amphotericin B deoxycholate is associated with nephrotoxicity, anemia, electrolyte disturbances (including hypokalemia and hypomagnesemia), renal tubular acidosis, and infusion-related reactions. These complications can contribute to treatment interruption and are associated with worse outcomes in some cohorts. Risk mitigation includes preinfusion hydration and proactive electrolyte monitoring/repletion; lipid formulations reduce toxicity and facilitate completion of induction therapy when available.[3][57][82]

• Flucytosine toxicities: Flucytosine can cause dose-dependent bone marrow suppression and hepatotoxicity, with gastrointestinal intolerance and occasional neurologic adverse effects. Toxicity risk increases with renal impairment due to drug accumulation; dose adjustment and close laboratory monitoring are essential, and therapeutic drug monitoring (when available) can reduce severe adverse events.[57]

• Fluconazole toxicities and interactions: Fluconazole is generally well tolerated but may cause hepatotoxicity and QT prolongation, particularly in patients with concurrent risk factors or interacting medications. Clinicians should review concomitant therapies for CYP-mediated interactions and for agents that affect fluconazole exposure or cardiac repolarization risk, and monitor liver enzymes during prolonged or high-dose courses when clinically indicated.[8]